IL33 and metabolic dysfunction-associated steatotic liver disease: However, other authors showed that treatment with recombinant IL-33 led to weight loss and improved hepatic steatosis, ALT, and IR in mice fed a HFD, but exacerbated hepatic fibrosis in both HFD and MCD diet NAFLD mice [110], as shown for IL-17 [66].